NASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $138.77 +7.43 (+5.66%) Closing price 04:00 PM EasternExtended Trading$138.62 -0.15 (-0.11%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Palvella Therapeutics Stock (NASDAQ:PVLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$128.80▼$139.8650-Day Range$128.00▼$158.1352-Week Range$65.93▼$161.38Volume174,037 shsAverage Volume261,311 shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/APrice Target$209.14Consensus RatingModerate Buy Company Overview Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited. Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement. Palvella has also evaluated its QTORIN platform in other rare dermatologic conditions, including manifestations associated with tuberous sclerosis complex. The company conducts its research and development activities primarily in the United States and works with clinicians and patient communities focused on rare diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania, and its programs remain centered on advancing specialized treatments through clinical development and regulatory review.AI Generated. May Contain Errors. Read More Palvella Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 692nd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPalvella Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalvella Therapeutics has a consensus price target of $209.14, representing about 51.5% upside from its current price of $138.01.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palvella Therapeutics are expected to decrease in the coming year, from ($6.40) to ($8.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -28.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palvella Therapeutics is -28.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalvella Therapeutics has a P/B Ratio of 58.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Palvella Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.49% of the float of Palvella Therapeutics has been sold short.Short Interest Ratio / Days to CoverPalvella Therapeutics has a short interest ratio ("days to cover") of 12.82, which indicates bearish sentiment.Change versus previous monthShort interest in Palvella Therapeutics has recently increased by 1.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest3 people have searched for PVLA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,526,138.00 in company stock.Percentage Held by Insiders17.20% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Stock News HeadlinesPalvella Therapeutics, Inc. (NASDAQ:PVLA) Stock Rated "Moderate Buy" by Wall Street AnalystsOctober 1, 2026 | americanbankingnews.comPalvella Therapeutics, Inc. Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For QTORIN? RapamycinSeptember 29, 2026 | marketscreener.comMMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 9 at 1:00 AM | The Oxford Club (Ad)Palvella Therapeutics - U.S. Food and Drug Administration Awards Additional Funding for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic MalformationsSeptember 29, 2026 | marketscreener.comMPalvella Therapeutics: FDA Handholding Makes The Regulatory Story StrongerSeptember 29, 2026 | seekingalpha.comPalvella Therapeutics Wins Additional US FDA Grant Funding for Rare Skin Disease DrugSeptember 28, 2026 | finance.yahoo.comPalvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of StockSeptember 19, 2026 | insidertrades.comPalvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 1,777 SharesSeptember 16, 2026 | insidertrades.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $104.67 at the beginning of the year. Since then, PVLA shares have increased by 31.9% and is now trading at $138.0110. How were Palvella Therapeutics' earnings last quarter? Palvella Therapeutics, Inc. (NASDAQ:PVLA) released its quarterly earnings data on Tuesday, August, 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by $0.35. Read the conference call transcript. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today10/09/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (21m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PVLA's financial health is in the Green zone, according to TradeSmith. PVLA has been in this zone for over 21 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PVLA Previous SymbolNASDAQ:PVLA CIK1583648 Webwww.palvellatx.com Phone(484) 253-1461Fax49-8161-141-1444Employees29Year Founded2015Price Target and Rating Average Price Target for Palvella Therapeutics$209.14 High Price Target$270.00 Low Price Target$133.00 Potential Upside/Downside+50.7%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.84% Return on Assets-38.33% Debt Debt-to-Equity RatioN/A Current Ratio21.18 Quick Ratio21.18 Sales & Book Value Annual Sales$42.81 million Price / Sales46.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book58.80Miscellaneous Outstanding Shares14,410,000Free Float11,930,000Market Cap$2.00 billion OptionableN/A Beta-0.27 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:PVLA) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
